Full Course Description


Essential Phrases in Medical Spanish for Nurse Practitioners

This workshop will help Nurse Practitioners communicate effectively in basic Spanish phrases. Participants will gain a primary understanding of the Spanish language, an overview of Spanish speaking cultures and an introduction to basic pronunciation, the alphabet, grammar, and vocabulary for conversational Spanish. Participants will be able to verbalize basic Spanish greetings, perform a basic health assessment, and speak in conversational medical phrases.

Program Information

Objectives

  1. Examine general cultural and language considerations for Spanish speaking patients. 
  2. Identify basic Spanish words and expressions related to healthcare situations. 
  3. Identify basic Spanish phrases needed to communicate with Spanish speaking patients in your role as a health care provider. 
  4. Determine resources available for health care providers to learn Spanish phrases and resources for non-English speaking patients to receive translated medical information. 
  5. Formulate a basic health screening and physical assessment in Spanish. 
  6. Use simple Spanish phrases to explain diagnostic test results, medications, and treatments. 
  7. Examine how to use a translator effectively. 

Outline

Lecture 1 - Fundamentals of Spanish
1. Introductions and basic greetings
2. Learning Spanish 
 
    1) Demographics of our nation
    2). Competencies of communication, safety and quality care
        Stories: ducharme, senor confused in 4-point restraints
    3). Fun and useful 2nd language 
3. Components of learning a foreign language 
a. Guidelines to learning a 2nd language: learn parts of speech/language, listen/train your ear, practice and speak
b. Parts of language: vocab, grammar, pronunciation, comprehension, fluency
c. Simple steps to learn a foreign language
4. Cultural Considerations
    a. Gender/machismo
    b. Time, space
    c. Attitudes of health and illness
    d. Religion and values, demonstration of affection, family
5. Vocab: alphabet, vowels, & cognates
a. Alphabet/vowels
b. Cognates, near cognates, cognate verbs
6. Grammar: question words
    a. parts of speech
    b. key phrases
    c. gender nouns
    d. articles
7. Dialog: How to Understand a Spanish Speaking Patient
8. Easy translation
    a. Guidelines to the Touch and Talk technique for health care providers
    b. How to Initiate a One-Word Response 
9.  Dicho: El tiempo lo cura todo. Time heals all wounds.
10. Spotlight- North America & Mexico

Lecture 2- The health care interview
1. Greeting phrases, using a dictionary.
2. Vocab: time, hour, numbers
3. Grammar: nouns and plurals, idioms
4. Question words for the healthcare interview, professions
5. Practice scenario: common health conditions and illnesses
6. Dicho: El remedio puede ser peor que la enfermedad.
    Sometimes the remedy is worse than the disease.
7. Culture-Spain

Lecture 3- Assessing Patients
1. Greeting: Yo soy_______.
2. Vocab: parts of the body
3. Grammar: Pronouns, Verbs AR, ER and IR, expressing a negative
4. Dialog: Creating the either/or questioning approach
5. Scenario: Stimulating the yes/no answers, ER visit
6. Dicho: Hacer de tripas corazón.
    What can't be cured must be endured.
7. Culture Focus: Belize, Guatemala, Honduras

Lecture 4    
1. Greeting/question to partner “Que trabajo hace?”
2. Vocab: family
3. Grammar-Irregular verbs IR: Tener, querer, ir
4. Dialog practice: case senarios w/Garcia family
5. Practice scenario- Neurological system and Integumentary system
6. Saying/Dicho: El que algo quiere, algo le cuesta.
    He that would have the fruit must climb the tree.
7. Cultural insight of a country-El Salvador, Dominican Republic, Nicaragua

Lecture 5     
1. Greeting/question to partner “Quien es en su familia?”
2. Vocab: food, medications
3. Grammar- prefixes/suffixes, possessives, verbs Ser and Estar
4. Dialog practice: medications, remedies, typical medical scenarios
5. Practice scenario-Cardiovascular system and respiratory scenario
6.  Saying/Dicho: Dime con quien andas, y te dire quien eres.
     You can judge a man by the company he keeps.
7. Cultural insight of a country-Panama, Costa Rica, Colombia

Lecture 6     
1. Greeting/question to partner “Que es su pasatiempo?” 
2. Vocab- directions, medical tests, equipment and settings
3. Grammar- verb forms
4. Dialog practice: diagnostic tests
5. Practice scenario-GI, GU and MS vocabulary
6 Saying/Dicho: Persevera y triunfaras.
   If at first you don't succeed, try, and then try again.
7. Cultural insight of a country-Chile, Uruguay, Paraguay Peru

Lecture 7    
1. Greeting/question to partner “Que le gusta comer?” 
2. Vocab- time, days of week, months of year, seasons
3. Grammar- prefixes, suffixes, adjectives, 
4. Dialog: giving a diagnosis, medical equipment, specialists
5. Practice scenario-Reproductive system & mental health
6. Saying/Dicho: Paga lo que debes, sanaras del mal que tienes
    Pay your debts and that will cure your disease.
7. Cultural insight of a country-Bolivia, Venezuela, Ecuador, Argentina

Lecture 8     
1. Greeting/question to partner “Que le gusta hacer?”
2. Vocab- clothing & colors
3. Grammar: mock scenarios and patient referrals and discharge
4. Dialog- when to use a translator effectively
5. Practice scenario- mock scenarios
6. Dicho: Change can renew your energy.
7. Cultural insight of a country- Islands
8. How to advance your Spanish
 

Target Audience

  • Nurse Practitioners

Copyright : 10/29/2025

Hypertension: Killing the Silent Killer

Join Dr. Sanul Corrielus, a board-certified cardiologist, best-selling author in heart health and CEO of Corrielus Cardiology to address the greatest challenges to manage hypertension. The 2017 ACC/AHA Hypertension Guideline introduced key changes in blood pressure classification and management, lowering the threshold for diagnosing hypertension. Normal blood pressure is now defined as <120/80 mm Hg, while hypertension is classified into elevated (120-129/<80 mm Hg), stage 1 (130-139/80-89 mm Hg), and stage 2 (≥140/90 mm Hg). This has increased the prevalence of hypertension, encouraging earlier detection and intervention. Lifestyle changes are advised for stage 1, but pharmacological treatment is recommended for stage 2 or stage 1 with cardiovascular disease or a 10-year ASCVD risk ≥10%. The guideline sets a blood pressure goal of <130/80 mm Hg for most adults and focuses on specific populations. African Americans at higher risk for complications may require thiazide diuretics or calcium channel blockers. For those with diabetes, tight control of blood pressure is vital to prevent complications, with the same target of <130/80 mm Hg. Older adults should aim for the same goal but with consideration of overall health. Resistant hypertension, where blood pressure remains uncontrolled with three agents, requires further evaluation. Adherence to treatment and lifestyle changes is critical for achieving and maintaining blood pressure control and reducing cardiovascular risks.

Program Information

Objectives

  1. Evaluate the salient aspects of 2017 ACC/AHA hypertension guidelines.
  2. Analyze the new classification of HBP and its impact on prevalence.
  3. Determine blood pressure thresholds and goals for pharmacological therapy.
  4. Plan treatment strategies for resistant hypertension.
  5. Evaluate current hypertension interventions for special populations, including: African Americans, patients with diabetes, and older adults.

Outline

  • ACC/AHA HTN guidelines
  • Population data and control
  • Physiology, pathophysiology, and genetics
  • Assessment and diagnosis
  • Resistant and secondary hypertension
  • Drugs and treatment
  • New therapies

Target Audience

  • Physicians 
  • Physician Assistants
  • Nurses

Copyright : 12/12/2024

Revolution in Diabetes Care

Diabetes management is evolving rapidly, with new medications, updated guidelines, and innovative approaches to optimizing glycemic control while minimizing complications. This one-hour session will explore the latest updates in pharmacologic treatment for diabetes, providing a comprehensive review of the nine major classes of diabetes medications, their mechanisms of action, and key clinical considerations.

Through an engaging lecture and interactive case study, gain practical insights into selecting the most effective treatments based on individual patient needs. Whether managing type 1 or type 2 diabetes, take away the knowledge to implement evidence-based strategies for improved patient outcomes. Stay ahead of the latest advancements and refine your approach to diabetes pharmacology!

Program Information

Objectives

  1. Evaluate the mechanism of action, benefits, and potential side effects of the nine major classes of current diabetes medications.
  2. Analyze pharmacologic treatment guidelines for diabetes stand the implications for patient care.
  3. Apply updated pharmacologic knowledge to practical diabetes medication decisions.

Outline

Diabetes Medication Classes

  • Biguanides (Metformin) – First-line therapy, insulin sensitivity
  • Sulfonylureas (Glipizide, Glyburide, Glimepiride) – Insulin secretion
  • Meglitinides (Repaglinide, Nateglinide) – Rapid-acting insulin secretion
  • Thiazolidinediones (Pioglitazone, Rosiglitazone) – Insulin sensitivity, risks
  • DPP-4 Inhibitors (Sitagliptin, Linagliptin, Saxagliptin) – Incretin effects
  • GLP-1 Receptor Agonists (Semaglutide, Liraglutide, Dulaglutide) – Weight loss, cardiovascular benefits
  • SGLT-2 Inhibitors (Empagliflozin, Dapagliflozin, Canagliflozin) – Renal and cardiovascular benefits
  • Insulin Therapy (Rapid, Basal, Mixed) – Individualizing therapy
  • Amylin analogues (Pramlintide) – Adjunct therapy for type 1 and type 2
Case Study Application to Practice
  • Patient scenario with comorbidities, A1C levels, and treatment barriers
  • Select appropriate pharmacologic interventions
  • Adjust therapy based on patient response and side effects

Target Audience

  • NPs
  • APRNs
  • PAs
  • PharmDs
  • MDs
  • DOs

Copyright : 05/16/2025

GERD, Dyspepsia and Barrett’s Esophagus: Treatment Updates for 2025

Please join Dr. Peter Burch, a double certified clinical gastroenterologist with over 30 years of specialty experience, to explore GERD in a practical, case based, and interaction session. He will provide the highlights on alarm signs with GERD, medical mimickers of GERD, making the correct diagnosis of GERD, clinical differences between PPIs, and discussion on Vonoprazan as a PPI alternative.

At the conclusion of the training, you will have the necessary clinical updates and tools to confidently manage patient with GERD, dyspepsia, and Barrett’s esophagus.

Program Information

Objectives

  1. Evaluate medical mimickers of GERD to make the right clinical diagnosis.
  2. Compare the clinical differences between PPIs.
  3. Discuss Vonoprazan as a PPI alternative.
  4. Plan to incorporate updates and tools to confidently manage patients with GERD, dyspepsia, and Barrett’s esophagus.

Outline

GERD

  • How to make the diagnosis of GERD
  • Factors that increase GERD
  • Unusual manifestations of GERD
  • PPI efficacy for unusual manifestations
  • Foods and meds that exacerbate GERD
  • Complications of GERD
Dyspepsia as a mimicker of GERD
  • Define dyspepsia/functional dyspepsia
  • How to distinguish dyspepsia/functional dyspepsia from GERD
Alarm “Signs” and GERD

Gastroparesis as a Mimicker of GERD
  • Etiologies and treatment of gastroparesis
Achalasia as a Mimicker of GERD
  • Treatment of achalasia
PPIs
  • Are there clinical differences among PPIs?
  • ”Tachyphylaxis”
  • PPI overuse
PPI Side Effects Discussion
  • Reality vs observational data
  • How to “de prescribe” PPIs
  • Reasons to continue PPIs
Vonoprazan
  • The new kid on the block
  • Benefits over PPIs
Barrett’s esophagus
  • Risk factors: Which women should be screened for Barrett’s
  • Cancer risk
  • Limitations of endoscopy
    • Accuracy of current guidelines to detect Ca
  • Do PPIs & NSAIDS prevent progression of Barrett’s to cancer
  • How to manage low grade dysplasia
  • Does Barrett’s ever disappear
  • What age should we stop Barret’s surveillance

Target Audience

  • NPs
  • APRNs
  • PAs
  • PharmDs
  • MDs
  • DOs

Copyright : 05/15/2025

Heart Failure: Diagnosis and Current Treatment Guidelines

With pronounced longevity and improved survival after myocardial infarcts, we see more patients than ever with heart failure. Patients with chronic low cardiac outputs can be a challenge to manage, especially as new medications and management tools become available every year. During this session, Cyndi Zarbano, MSN-Ed, CCRN, CMSRN, LNC, will explore emergency interventions for acute decompensation, causes, and new management guidelines to treat and slow the progression of the heart failure disease process. Discover best practice strategies to prevent and manage heart failure exacerbations!

Program Information

Objectives

  1. Analyze current guidelines for treating different forms of heart failure to slow progression and to improve mortality rates.
  2. Explore current medication regimens and when each is appropriate for patients.
  3. Recognize the strengths and limitations of laboratory findings in patients with heart failure.
  4. Determine the clues on an EKG that could identify acute changes in cardiac long-term function.

Outline

Metabolic Syndrome

  • What are some of the problems we are facing?
Types of Heart Failure
  • LV Systolic Failure
  • LV Diastolic Failure
  • Cor Pulmonale
Classification Systems
  • NYHA
  • AHA
Tests
  • Labs
    • BNP
    • Pro-BNP
    • Troponins
  • ECK Clues
  • ECHO Clues
  • Heart Cath
    • Right-sided
    • Left-sided
Current Medications Based on the Type of Failure
  • Improving function
  • Slowing progression
Tools
  • IABP
  • Impella’s
  • VAD’s
  • PPM’s/ICD’s

Target Audience

  • Physicians 
  • Physician Assistants
  • Nurses

Copyright : 12/13/2024

Ethnogeriatrics: Honoring Elderly Cultural Preferences in Healthcare

Culture plays a significant role in how individuals view themselves and their role in the family and the world around them. Therefore, patients’ approach to their healthcare needs, including illness and death, is directly impacted by cultural factors. When caring for the aging populations, you should personalize care with the patient’s cultural factors in mind. Latasha Ellis, PhD, LCSW, LISW-CP, OSW-C, will provide important factors and practices to consider when delivering culturally responsive healthcare services to the elderly population.

Program Information

Objectives

  1. Analyze culture and cultural humility.
  2. Enhance awareness of unique healthcare needs for diverse ethnic backgrounds.
  3. Improve the healthcare experience for elderly patients while honoring cultural preferences.

Outline

Cultural Competence and Cultural Humility

  • Culture
  • Culture humility
  • Provider’s self-assessment
Unique Healthcare Needs for Diverse Ethnic Backgrounds
  • Race/ethnicity
  • Religion
  • Geographical region
  • Socio-economic status
  • Social drivers of health
Caring for the Aging Population
  • Meaning and purpose (Viktor Frankel)
  • Family dynamics
  • Preparing for end of life

Target Audience

  • Registered Nurses
  • Nurse Practitioners
  • Physicians
  • Physician Assistants
  • Physical Therapists
  • Physical Therapist Assistants
  • Occupational Therapists
  • Occupational Therapy Assistants
  • Speech Language Pathologists
  • Social Workers
  • Counselors
  • Nursing Home Administrators

Copyright : 10/17/2025

Lipid Logic: An Update on Current and Future Pharmacologic Approaches to Dyslipidemia Management

Dyslipidemia management requires a multifaceted approach that includes both lifestyle modifications and pharmacotherapy. The primary goal of treatment is to reduce LDL-C levels to lower cardiovascular (CV) risk. Additionally, some patients may require other therapies to address residual CV risk associated with elevated triglycerides or elevated lipoprotein(a) [Lp(a)].

The 2018 AHA/ACC/Multisociety cholesterol guideline emphasized the importance of lowering LDL-C as the primary treatment target. This guideline focuses on populations where statin therapy has been proven to lower both LDL-C and CV event risk, known as the four statin benefit groups. In 2022, the ACC published an Expert Consensus Decision Pathway for nonstatin therapy, recommending specific LDL-C thresholds for all four statin benefit groups, rather than just two as per the 2018 guideline. While statin therapy is effective in reducing CV risk and LDL-C levels, some patients may require additional nonstatin therapies to achieve optimal LDL-C reduction. Several nonstatin therapies, including ezetimibe, bempedoic acid, PCSK9 monoclonal antibodies, and inclisiran, are available and effective in further lowering LDL-C. This program will review these LDL-C lowering therapies and their optimal use to improve patient outcomes.

Even when LDL-C is reduced to recommended levels, patients with elevated triglycerides or Lp(a) remain at increased risk for CV events. Clinicians should be aware of the evidence linking elevated triglycerides and Lp(a) with CV events, as well as the latest innovations and outcomes data related to current and emerging drug therapies for these conditions. This session will review outcomes data on the use of omega-3 fatty acids in patients with elevated triglycerides. Additionally, it will cover two medications in phase III trials, pelacarsen and olpasiran, which lower Lp(a) in conjunction with statin therapy.

Program Information

Objectives

  1. Evaluate the 2018 AHA/ACC/Multisociety cholesterol guideline and 2022 ACC Expert Consensus Decision Pathway on nonstatin therapy recommendations.
  2. Compare the mechanisms of action, efficacy, and outcomes data for currently approved and emerging drug therapies for LDL-C lowering.
  3. Determine recommended treatments for patients with elevated triglycerides according to the 2021 ACC Expert Consensus Decision Pathway on hypertriglyceridemia.
  4. Analyze novel and emerging medications for LDL-C lowering and Lp(a) lowering.

Outline

LDL-C Lowering

  • Expert consensus recommendations
    • 2018 AHA/ACC/Multisociety Cholesterol Guidelines
    • 2022 ACC Expert Consensus Decision Pathway on nonstatins
  • Pharmacotherapy options
    • Statins
    • Ezetimibe
    • Bempedoic acid
    • PCSK9 monoclonal antibodies
    • Inclisiran
Triglyceride Lowering
  • 2021 ACC Expert Consensus Decision Pathway on hypertriglyceridemia
  • Pharmacotherapy options
    • Fibric acid derivatives
    • Omega-3 fatty acids
Lp(a)
  • What is Lp(a)
  • Effect of approved LDL-C lowering medications on Lp(a)
  • Emerging pharmacotherapies
    • Pelacarsen
    • Olpasiran

Target Audience

  • Physicians 
  • Physician Assistants
  • Nurses

Copyright : 12/12/2024

Being a Healer: Privilege of Providers

Being a Healer is an informative session on the holistic nature of care, with a description of effective practices to promote healing as a provider. The focus of the session provides practical and affirming tips for providers, as it relates to the clinician’s role in the healing process.

Program Information

Objectives

  1. Evaluate the definition of healing, as it relates to treatment plans of care.
  2. Identify key components of care, as they correlate with holistic care and healing

Outline

Define Healing

  • Evidence on the definition of healing
  • Role of clinicians in healing
  • Measurable outcomes of healing in patient care
Integration of Healing in Treatment Plans
  • Sample case reviews with healing principles integrated in care
Measurable Outcomes of Healing
  • Evidence-based practice measurements for healing progress
  • Distinguish quality and quantity of life
Effective Methods of Healing – With a Focus on Everyday Practice

Target Audience

  • NPs
  • APRNs
  • PAs
  • PharmDs
  • MDs
  • DOs

Copyright : 05/16/2025